The phase 3 LEAP-015 trial evaluated the efficacy and safety of pembrolizumab with lenvatinib in patients with advanced/metastatic gastroesophageal cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback